Skip to main content

Table 1 Baseline characteristics and adverse outcomes of the 57 patients

From: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study

Baseline characteristics and outcome events Results
Age, years 75.4 ± 9.4
Sex
 Female, n (%) 9 (16)
 Male, n (%) 48 (84)
Body height, cm 162.2 ± 7.7
Body weight, kg 63.5 ± 10.8
Body mass index, kg/m2 24.0 (21.5 to 26.5)
Body surface area, m2 1.67 ± 0.15
Charlson comorbidity index 5 (3 to 6)
Echocardiographic evidence of pulmonary hypertension, n (%) 36 (63)
Echocardiographic evidence of LV dysfunction, n (%) 2 (4)
Dyslipidaemia, n (%) 26 (46)
Chronic hepatitis B, n (%) 6 (11)
Chronic hepatitis C, n (%) 5 (9)
Other non-viral liver condition, n (%) 3 (5)
Fatty liver on baseline sonography, n (%) 15 (26)
Cigarette smoking status
 Never smoker, n (%) 26 (46)
 Current smoker, n (%) 4 (7)
 Former smoker, n (%) 27 (47)
Baseline plasma KL-6 level, ng/mL 1.48 (0.55 to 2.82)
Baseline plasma SPA level, pg/mL 283.6 (157.3 to 435.4)
Baseline oximetry breathing ambient air, % 95 (93 to 97)
Baseline DLCO, mmol/min/kPa 2.78 (2.11 to 3.96)
Baseline DLCO, % predicted 55 (38 to 70)
Baseline FVC, L 2.02 ± 0.49
Baseline FVC, % predicted 67 ± 12
Stages based on the GAP index
 Stage 1, n (%) 14 (25)
 Stage 2, n (%) 31 (54)
 Stage 3, n (%) 12 (21)
Nintedanib-related hepatic injury, n (%) 24 (42)
On-treatment AE-IPF, n (%) 20 (35)
On-treatment mortality, n (%) 16 (28)
Duration of nintedanib therapy, days 345 (91 to 706)
Time to first nintedanib-related hepatic injury, days 69 (17 to 156)
Time to first on-treatment AE-IPF, days 238 (111 to 431)
Time to on-treatment mortality, days 486 (217 to 811)
Time between plasma sampling and nintedanib initiation, days 6 (0 to 28)
Time between baseline pulmonary functions and nintedanib initiation, days 28 (16 to 51)
Time between plasma sampling and baseline pulmonary functions, days 24 (12 to 81)
Annual rate of change in FVC, L/52 weeks − 0.13 (− 0.26 to + 0.06)
Annual rate of change in DLCO, % predicted/52 weeks − 9 (− 29 to − 2)
  1. Categorical data are presented as counts and percentages, and continuous variables were presented as mean (± standard deviation) or median (interquartile range) if non-normally distributed. AE-IPF, acute exacerbation of idiopathic pulmonary fibrosis; DLCO, diffusion capacity for carbon monoxide; FVC, forced vital capacity; GAP, gender, age, physiology; KL-6, Krebs von den Lungen-6; LV, left ventricular; SPA, surfactant protein A
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us